Total bilirubin = 4 mg/dL, direct = 3.5 mg/dL
Quality depends on the compounding pharmacy
Pulmonary : potential indications to check an ammonia level New-onset moderate-to-severe encephalopathy without another clear etiology
Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play
Back Finkelstein, EA, Trogdon, JG, Cohen, JW (2009) 'Annual medical spending attributable to obesity: payer-and service-specific estimates', Health Affairs , 28/5, w82231
